Boston Scientific (BSX) UBS Global Healthcare Conference 2024 summary

Financial performance and growth outlook

• Achieved 18.2% organic revenue growth and 27% EPS growth in Q3, with broad-based business strength and high operating margins in 2024.

• Strong momentum and growth catalysts expected to continue into 2025, with formal guidance to be provided early next year.

Innovation and product development

• FARAPULSE is rapidly transforming the AFib ablation market, with accelerated adoption and high user satisfaction due to ease of use, safety, and efficacy.

• Ongoing innovation includes new iterations of FARAWAVE and the upcoming FARAPOINT in 2025, aiming to maintain a competitive edge.

• Integration of mapping systems and new catheter designs are enhancing procedural efficiency and expanding clinical applications.

Market expansion and competitive dynamics

• FARAPULSE adoption is outpacing expectations, with a first-mover advantage and majority share in Europe, and rapid launches in China and Japan targeting multi-billion-dollar opportunities.

• The competitive moat is reinforced by continuous innovation, strong clinical evidence, and trusted relationships with electrophysiologists and cardiologists.

• Hospitals are increasing capacity and adapting workflows to meet growing demand for AF ablation procedures.